Role of Jagged1/STAT3 Signalling in Platinum-resistant Ovarian Cancer

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2019 Apr 18

PMID 30993885

Citations 27

Authors

Jiang Yang

Hui Xing

Danhua Lu

Jun Wang

Bingshu Li

Jianming Tang

Fengqin Gu

Li Hong

Affiliations

Soon will be listed here.

Abstract

Jagged1, the essential ligand of the Notch signalling pathway, is highly expressed in metastatic prostate cancer, and its high expression in breast cancer is linked to poor survival rates. However, the mechanism of Jagged1's involvement in platinum-resistant ovarian cancer has not been thoroughly elucidated to date. The purpose of the present study was to investigate the roles of Jagged1 in the platinum resistance of ovarian cancer and its possible mechanisms. Compared with a platinum responsive group of ovarian epithelial cell carcinomas, we found the positive staining intensity of Notch1, Notch2, Jagged1, STAT3 and Epithelial-mesenchymal transition (EMT) proteins were lower in a platinum-resistant group. The DDP-resistant ovarian cancer cell line (C13K) had a higher IC50 of DDP than its parental cell line (OV2008) (P < 0.05) and acquired an EMT phenotype and invasive characteristics. Inhibiting or knockdown of Jagged1 expression could not only reduce its capacity of migration and invasion but also reverse EMT and down-regulate the expression of serine 727-phosphorylated STAT3 (pS727) at the protein level but not total STAT3 or tyrosine 705-phosphorylated STAT3 (pY705) in C13K cells. Furthermore, it was found that crosstalk between the Jagged1/Notch and JAK/STAT3 signalling pathways were involved in Jagged1-promoting EMT in C13K cells. Experiments in vivo showed a reduced micrometastatic tumour burden in the lung, liver and spleen of mice implanted with C13K cells with knocked-down Jagged1 compared with mice implanted with control cells. All of these results demonstrate that Jagged1 can crosstalk with the JAK/STAT3 pathway, and they all cooperate to promote the aberrant occurrence of EMT, further reinforcing the abilities of invasion and migration of platinum-resistant ovarian cancer in vivo and in vitro.

Citing Articles

Notch signaling pathway in cancer: from mechanistic insights to targeted therapies.

Shi Q, Xue C, Zeng Y, Yuan X, Chu Q, Jiang S Signal Transduct Target Ther. 2024; 9(1):128.

PMID: 38797752 PMC: 11128457. DOI: 10.1038/s41392-024-01828-x.

Jagged1 intracellular domain/SMAD3 complex transcriptionally regulates TWIST1 to drive glioma invasion.

Kim J, Hong N, Park S, Ham S, Kim E, Kim S Cell Death Dis. 2023; 14(12):822.

PMID: 38092725 PMC: 10719344. DOI: 10.1038/s41419-023-06356-0.

Biomedical engineering approaches for the delivery of JAGGED1 as a potential tissue regenerative therapy.

Kaimari S, Kamalakar A, Goudy S Front Bioeng Biotechnol. 2023; 11:1217211.

PMID: 37781534 PMC: 10534981. DOI: 10.3389/fbioe.2023.1217211.

Ascites-Derived Organoids to Depict Platinum Resistance in Gynaecological Serous Carcinomas.

Arias-Diaz A, Ferreiro-Pantin M, Barbazan J, Perez-Beliz E, Ruiz-Banobre J, Casas-Arozamena C Int J Mol Sci. 2023; 24(17).

PMID: 37686015 PMC: 10487816. DOI: 10.3390/ijms241713208.

APEX1 predicts poor prognosis of gallbladder cancer and affects biological properties of CD133 GBC-SD cells via upregulating Jagged1.

Wu Z, Liu Z, Sun Y, Yuan Y, Zou Q, Wen Y J Cancer. 2023; 14(8):1443-1457.

PMID: 37283798 PMC: 10240672. DOI: 10.7150/jca.83356.

References

Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B . Targeting Notch to target cancer stem cells. Clin Cancer Res. 2010; 16(12):3141-52. PMC: 3008160. DOI: 10.1158/1078-0432.CCR-09-2823. View

Zavadil J, Cermak L, Soto-Nieves N, Bottinger E . Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. EMBO J. 2004; 23(5):1155-65. PMC: 380966. DOI: 10.1038/sj.emboj.7600069. View

Zheng X, Carstens J, Kim J, Scheible M, Kaye J, Sugimoto H . Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015; 527(7579):525-530. PMC: 4849281. DOI: 10.1038/nature16064. View

Alniaimi A, Demorest-Hayes K, Alexander V, Seo S, Yang D, Rose S . Increased Notch1 expression is associated with poor overall survival in patients with ovarian cancer. Int J Gynecol Cancer. 2015; 25(2):208-13. DOI: 10.1097/IGC.0000000000000359. View

Yang J, Xing H, Lu D, Wang J, Li B, Tang J . Role of Jagged1/STAT3 signalling in platinum-resistant ovarian cancer. J Cell Mol Med. 2019; 23(6):4005-4018. PMC: 6533470. DOI: 10.1111/jcmm.14286. View

Yang Y, Ahn Y, Gibbons D, Zang Y, Lin W, Thilaganathan N . The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. J Clin Invest. 2011; 121(4):1373-85. PMC: 3069760. DOI: 10.1172/JCI42579. View

Mao Y, Xu J, Li Z, Zhang N, Yin H, Liu Z . The role of nuclear β-catenin accumulation in the Twist2-induced ovarian cancer EMT. PLoS One. 2013; 8(11):e78200. PMC: 3823872. DOI: 10.1371/journal.pone.0078200. View

Thiery J . Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002; 2(6):442-54. DOI: 10.1038/nrc822. View

Androutsellis-Theotokis A, Leker R, Soldner F, Hoeppner D, Ravin R, Poser S . Notch signalling regulates stem cell numbers in vitro and in vivo. Nature. 2006; 442(7104):823-6. DOI: 10.1038/nature04940. View

10.

Reedijk M, Pinnaduwage D, Dickson B, Mulligan A, Zhang H, Bull S . JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer. Breast Cancer Res Treat. 2007; 111(3):439-48. DOI: 10.1007/s10549-007-9805-3. View

11.

Zhou J, Jain S, Azad A, Xu X, Yu H, Xu Z . Notch and TGFβ form a positive regulatory loop and regulate EMT in epithelial ovarian cancer cells. Cell Signal. 2016; 28(8):838-49. DOI: 10.1016/j.cellsig.2016.03.016. View

12.

Zhao C, Li H, Lin H, Yang S, Lin J, Liang G . Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism. Trends Pharmacol Sci. 2015; 37(1):47-61. DOI: 10.1016/j.tips.2015.10.001. View

13.

Nieto M, Huang R, Jackson R, Thiery J . EMT: 2016. Cell. 2016; 166(1):21-45. DOI: 10.1016/j.cell.2016.06.028. View

14.

Christiansen J, Rajasekaran A . Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res. 2006; 66(17):8319-26. DOI: 10.1158/0008-5472.CAN-06-0410. View

15.

Rajan P, McKay R . Multiple routes to astrocytic differentiation in the CNS. J Neurosci. 1998; 18(10):3620-9. PMC: 6793143. View

16.

Liu J, Sato C, Cerletti M, Wagers A . Notch signaling in the regulation of stem cell self-renewal and differentiation. Curr Top Dev Biol. 2010; 92:367-409. DOI: 10.1016/S0070-2153(10)92012-7. View

17.

Wang Z, Li Y, Banerjee S, Sarkar F . Emerging role of Notch in stem cells and cancer. Cancer Lett. 2008; 279(1):8-12. PMC: 2699045. DOI: 10.1016/j.canlet.2008.09.030. View

18.

Santagata S, Demichelis F, Riva A, Varambally S, Hofer M, Kutok J . JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res. 2004; 64(19):6854-7. DOI: 10.1158/0008-5472.CAN-04-2500. View

19.

Ricci F, Fratelli M, Guffanti F, Porcu L, Spriano F, DellAnna T . Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy. Oncotarget. 2016; 8(5):7441-7451. PMC: 5352333. DOI: 10.18632/oncotarget.7465. View

20.

Wendt M, Balanis N, Carlin C, Schiemann W . STAT3 and epithelial-mesenchymal transitions in carcinomas. JAKSTAT. 2014; 3(1):e28975. PMC: 4024059. DOI: 10.4161/jkst.28975. View